DBV Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Pharming Group N.V. Announces Presentation Of New Ruconest Clinical Data
Pharming Group N.V. announced that it has presented clinical safety and efficacy data for Ruconest (recombinant human C1 inhibitor, or rhC1INH) at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI), Geneva, Switzerland, 16 to 20 June 2012. The new data covers a number of aspects that are relevant to the increasing number of physicians that use Ruconest in the day-to-day treatment of HAE patients in the European Union: Efficacy and safety data for Ruconest in the treatment of adolescents suffering from acute attacks of HAE; underpinning a potential extension of the European labeling of Ruconest and "real-life" experience by French physicians; building confidence in Ruconest by successful treatment with Ruconest of a HAE patient that previously failed various other treatments. In addition an analysis of a previously reported open-label study to explore potential benefits of Ruconest in prophylaxis of HAE, potentially an additional indication that could be explored. RUCONEST Phase III Study Pharming is conducting a Phase III clinical study with RUCONEST under a Special Protocol Assessment (SPA) that is intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Latest Developments for DBV Technologies SA
Latest Key Developments in Pharmaceuticals
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 Million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Share this
- Digg this